Immunogenicity and Safety of NBP608 Compared to Zostavax in Healthy Adult Aged 50 and Over

Phase 3CompletedNCT03120364

SK Chemicals Co., Ltd.824 enrolled

Overview

This study assesses non-inferiority by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax which are evaluated by gpELISA (Glycoprotein Enzyme Linked Immunosorbent Assay). Total of 824 healthy subjects (412 subjects per treatment arm) aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned.

This is a multi-center, randomized, double blinded, parallel-group study to assess the Immunogenicity and safety of NBP608 compared to Zostavax which are indicated for the prevention of herpes zoster. Total of 824 healthy subjects aged 50 and over are enrolled, and each subject is administered with single dose of vaccine which is randomly assigned in 1:1 ratio. Stratified randomization for age group is used to achieve the balance of treatment assignment within age strata. Total of five visits are scheduled including two visits via telephone contact. Blood sampling is conducted for immunogenicity assessment before and 6 weeks after vaccination at Visit 2 and Visit 4 respectively. Safety is monitored 1 week, 6 weeks and 26 weeks after vaccination through Visit 3\*, Visit 4 and Visit 5\* (\* telephone contact)

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

824

Conditions

Herpes Zoster

Interventions

NBP608BIOLOGICAL

Preparation of Oka/SK strain of live, attenuated zoster virus

ZostavaxBIOLOGICAL

Preparation of Oka/Merck strain of live, attenuated zoster virus

Eligibility

Sex: ALLMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy adult over aged 50 years * Menopause females or females who are confirmed to be negative in a preganacy test on the day of screening and agree to practice birth control for 6 weeks after signing informed concent Exclusion Criteria: * Those with hypersensitivity to any component of IP(Investigational Product), such as gelatin * Those with a history of hypersensitivity to vaccination, such as Guillain-Barre syndrome * Those who have received antiviral agents witin 1 month prior to IP vaccination (topical antiviral agent is allowed) * Those who have previously received herpes zoster vaccine * Those who have a history of herpes zoster * Those with congenital or acquired immunodeficiency * Those with active untreated tuberculosis * Those who have received blood products or immunoglobulin within 3 months prior to IP(Investigational Products) vaccination * Those who have received other IPs(Investigational Products) in another clinical study witin 4 weeks prior to IP vaccination in this study

Locations (1)

Korea University Guro Hospital

Seoul, Guro-gu, South Korea

Outcomes

Primary Outcomes

GMR(Geometric Mean Ratio) of VZV(Varicella-Zoster Virus) antibody titer measured by gpELISA(Glycoprotein Enzyme-Linked Immnosorbent Assay)

The geometric mean fold rise of subjects' VZV(Varicella zoster virus) antibody titers of NBP608 from prevaccination to 6weeks postvaccination

Time frame: 6 weeks after IP(Investigational Product) vaccination

GMR(Geometric Mean Ratio) ratio of NBP608 to Zostavax measured by gpELISA

Non-inferiority assessment by comparing GMR(Geometric Mean Ratio) of NBP608 to Zostavax

Time frame: 6 weeks after IP(Investigational Product) vaccination

Secondary Outcomes

VZV-CMI(Varicella Zoster Virus-Cell Mediated Immnogenicity) response measured by IFN-γ(Interferon-gamma) ELISPOT (Enzyme-Linked Immunospot)

Time frame: 6 weeks after IP(Investigational Product) vaccination

VZV-CMI(Varicella Zoster Virus-Cell Mediated Immnogenicity) response measured by IL-2(Interleukin-2) ELISPOT (Enzyme-Linked Immunospot)

Time frame: 6 weeks after IP(Investigational Product) vaccination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.